Spectrum Pharmaceuticals Agrees to Acquire Allos Therapeutics After Apaziquone Setback

Cartwright, Heather
April 2012
PharmaDeals Review;2012, Vol. 2012 Issue 4, p55
Spectrum Pharmaceuticals has agreed to buy the cancer drug developer Allos Therapeutics for US$1.82 per share in cash, which represents a 27% premium over Allos' closing price prior to the announcement of the transaction. Allos shareholders will also receive a contingent value right that entitles them to a cash payment of US$0.11 per share if certain European regulatory approval and commercialisation milestones for Allos' lead cancer drug Folotyn® (pralatrexate injection) are achieved. The deal was announced just minutes after Spectrum disclosed that its bladder cancer drug apaziquone had failed to meet its primary end-point in two Phase III trials.


Related Articles

  • Amid Setback, Spectrum Pharma to Buy Allos.  // MondayMorning;4/9/2012, Vol. 20 Issue 15, p1 

    The article discusses the failure of experimental drug to treat a common form of bladder cancer which resulted in lowering of Spectrum Pharmaceuticals Inc. shares by 12 percent. Spectrum was testing a drug for non-muscle invasive bladder tumors, which are currently removed through surgery which...

  • Spectrum Pharmaceuticals to Acquire Allos Therapeutics: Acquisition Expected to Be Accretive on a Cash Basis in Q4 of 2012.  // Biomedical Market Newsletter;4/7/2012, Vol. 21, p1 

    The article presents information on an announcement made by Spectrum Pharmaceuticals Inc. and Allos Therapeutics Inc. on an agreement according to which Spectrum Pharmaceuticals will acquire all of the outstanding shares of Allos Therapeutics . Allos Therapeutics is a provider of Folotyn, a...

  • Spectrum Pharmaceuticals and Allos Therapeutics Announce Additional Extension of Tender Offer Period for Shares of Allos Therapeutics.  // Biomedical Market Newsletter;6/25/2012, Vol. 21, p1 

    The article informs that Spectrum Pharmaceuticals Inc. has extended its tender offer for purchasing all the outstanding shares of common stock of Allos Therapeutics Inc. It further informs that Spectrum is involved in the marketing of its oncology drugs including FUSILEV and ZEVALIN. It mentions...

  • Other Cancer News Headlines January 15, 2004--February 14, 2004.  // PharmaWatch: Cancer;March 2004, Vol. 3 Issue 3, p20 

    Presents news update on drug developments targeting various cancers, compiled as of February 14, 2004. NeoPharm's agreement with Food and Drug Administration (FDA) on phase III trial for its experimental anticancer drug; Plan of FDA to review Allos' application for a brain cancer drug;...

  • Today's Transactions: Spectrum Subsumes Allos.  // Mergers & Acquisitions Report;4/9/2012, Vol. 25 Issue 15, p17 

    The article reports on the decision of Spectrum Pharmaceuticals Inc. to acquire biopharmaceutical firm Allos Therapeutics Inc. for about 206 million U.S. dollars, or 1.82 U.S. dollars per share in cash.

  • Spectrum Pharmaceuticals Announces Impressive Responses in Difficult to Treat Carcinomas with SPI-1620 in a Phase I Study.  // Biomedical Market Newsletter;9/26/2011, Vol. 21, p554 

    The article reports that Spectrum Pharmaceuticals Inc. has presented the first part topline data for its phase 1 research on SPI-1620 at the 12th International Conference on Endothelin, held in Cambridge, England from September 11-14, 2011. It says that phase 1 study focuses on assessing the...

  • Decisions Update.  // PharmaWatch: Biotechnology;Dec2006, Vol. 5 Issue 12, p10 

    The article offers news briefs related to biotechnology in the U.S. for the year 2006. Gamida Cell has agreed with the U.S. Food and Drug Administration (FDA) on the design of a study of StemEx for the treatment of hematological malignancies. Allos Therapeutics Inc. has been recommended by an...

  • Allos initiates enrollment in Phase IIb lung cancer trial.  // PharmaWatch: Cancer;Feb2008, Vol. 7 Issue 2, p15 

    The article provides information about Allos Therapeutics Inc.'s clinical trial for non-small cell lung cancer (NSCLC) treatment. Allos reported that it will be conducting a Phase IIb, randomized, multi-center study comparing the efficacy of PDX to that of Tarceva, in patients with NSCLC. Pablo...

  • Cancer News Round-up.  // PharmaWatch: Monthly Review;Oct2007, Vol. 6 Issue 10, p4 

    The article offers news briefs in the pharmaceutical industry, particularly in the treatment of cancer. Allos Therapeutics Inc. has begun patient enrollment for a Phase I, open-label, multi-center study of its treatment for patients with relapsed or refractory cutaneous T-cell lymphoma....


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics